Abstract
Platelet aggregation in vitro to several aggregating agents (serotonin (5-HT), adenosine diphosphate, adrenaline and collagen) was studied in 16 patients with primary and secondary Raynaud's phenomenon and compared with that in 13 normal volunteers. Platelets from patients with Raynaud's phenomenon had significantly greater responses to all the 5-HT concentrations tested (p less than 0.001 for 10 microM; p less than 0.01 for 1 microM; p less than 0.05 for 0.1 microM; p less than 0.02 for 0.025 microM) and to low doses of adenosine diphosphate (p less than 0.01 for 1 microM; p less than 0.02 for 0.5 microM) but normal responses to collagen, adrenaline, and high doses of adenosine diphosphate. Patients with secondary Raynaud's phenomenon were significantly more hypersensitive to 0.5 microM adenosine diphosphate than patients with primary Raynaud's phenomenon. In patients with secondary Raynaud's phenomenon there was a significant correlation between the extent of 5-HT aggregation and the duration of the disease. The finding that platelets from patients with Raynaud's phenomenon have enhanced responses to 5-HT and adenosine diphosphate, but normal responses to adrenaline and collagen, is consistent with a role for 5-HT in this disease.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Biondi M. L., Marasini B., Bianchi E., Agostoni A. Plasma free and intraplatelet serotonin in patients with Raynaud's phenomenon. Int J Cardiol. 1988 Jun;19(3):335–339. doi: 10.1016/0167-5273(88)90238-0. [DOI] [PubMed] [Google Scholar]
- Hutton R. A., Mikhailidis D. P., Bernstein R. M., Jeremy J. Y., Hughes G. R., Dandona P. Assessment of platelet function in patients with Raynaud's syndrome. J Clin Pathol. 1984 Feb;37(2):182–187. doi: 10.1136/jcp.37.2.182. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kallenberg C. G., Vellenga E., Wouda A. A., The T. H. Platelet activation, fibrinolytic activity and circulating immune complexes in Raynaud's phenomenon. J Rheumatol. 1982 Nov-Dec;9(6):878–884. [PubMed] [Google Scholar]
- Lukác J., Rovenský J., Tauchmannová H., Zitnan D. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial. Drugs Exp Clin Res. 1985;11(9):659–663. [PubMed] [Google Scholar]
- Marasini B., Biondi M. L., Bianchi E., Dell'Orto P., Agostoni A. Ketanserin treatment and serotonin in patients with primary and secondary Raynaud's phenomenon. Eur J Clin Pharmacol. 1988;35(4):419–421. doi: 10.1007/BF00561375. [DOI] [PubMed] [Google Scholar]
- Reilly I. A., Roy L., Fitzgerald G. A. Biosynthesis of thromboxane in patients with systemic sclerosis and Raynaud's phenomenon. Br Med J (Clin Res Ed) 1986 Apr 19;292(6527):1037–1039. doi: 10.1136/bmj.292.6527.1037. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Roald O. K., Seem E. Treatment of Raynaud's phenomenon with ketanserin in patients with connective tissue disorders. Br Med J (Clin Res Ed) 1984 Sep 8;289(6445):577–579. doi: 10.1136/bmj.289.6445.577. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Seibold J. R., Terregino C. A. Selective antagonism of S2-serotonergic receptors relieves but does not prevent cold induced vasoconstriction in primary Raynaud's phenomenon. J Rheumatol. 1986 Apr;13(2):337–340. [PubMed] [Google Scholar]
- Williams R. C., Jr, Froelich C. J., Kilpatrick K., Crowe W. E., Levinson J. E. T gamma subset specificity of lymphocyte reactive factors in juvenile rheumatoid arthritis and systemic lupus erythematosus sera. Arthritis Rheum. 1981 Apr;24(4):585–591. doi: 10.1002/art.1780240403. [DOI] [PubMed] [Google Scholar]
- Zahavi J., Hamilton W. A., O'Reilly M. J., Leyton J., Cotton L. T., Kakkar V. V. Plasma exchange and platelet function in Raynaud's phenomenon. Thromb Res. 1980 Jul 1;19(1-2):85–93. doi: 10.1016/0049-3848(80)90406-5. [DOI] [PubMed] [Google Scholar]